Effect of Kinesio Taping on Pain, Posture and Function in Lower Cross Syndrome

Effect of Kinesio Taping on Pain, Posture and Function in Patient With Lower Cross Syndrome

Determine the impact of Kinesio taping on pain, postural alignment and functional outcomes in individuals with lower cross syndrome.

Participants with lower cross syndrome who present to physical therapy department will be screened for eligibility on basis of inclusion and exclusion criteria. Group A will receive the treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles along with Kinesiotaping using inhibition and facilitation technique for LCS and Group B will receive the treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles. The patients will receive the treatment sessions 3 days per week for almost 04 weeks. They will be evaluated after the treatment for PAIN, POSTURAL ASSESSMENT, FUNCTIONAL DISABILITY in order to check for the effect of the treatment.

Inclusion Criteria:

• Age- 30 to 50 years.
• Female patients.
• Anterior pelvic tilting > 7-10 degrees.
• Postural imbalance characterized by anterior pelvic tilt, lumbar hyper lordosis, and associated muscle imbalances.
• Discomfort, pain, or limitations related to the lower back, pelvis, and hips attributed to LCS.
• Willing to provide informed consent to participate in the study.

Exclusion Criteria:

• Musculoskeletal pathologies affecting the lower back, pelvis, hips, or lower extremities (e.g., herniated disc, lumbar radiculopathy, lumbar stenosis, hip labral tear).
• Kinesiotaping interventions for LCS in the past 3 months.
• Allergies to tape materials or skin sensitivities that might prevent safe tape application.
• Pregnant individuals due to potential discomfort.
• Open wounds, infections, or skin conditions at the taping application site.
• Severe cardiovascular, pulmonary, renal, or neurological diseases.
• In other clinical trials involving interventions for LCS.